IDERA PHARMACEUTICALS ANNOUNCES IMMUNO-ONCOLOGY CLINICAL RESEARCH COLLABORATION WITH ABBVIE
[caption id="attachment_9277" align="aligncenter" width="747"] Press Release[/caption]
EXTON, Pa.,?Sept. 04, 2019?(GLOBE NEWSWIRE) --?Idera Pharmaceuticals, Inc.?(NASDAQ: IDRA) announced today that they have entered into an immuno-oncology clinical research collaboration with?AbbVie, a global, research-based biopharmaceutical company.? The purpose of the collaboration is to conduct a clinical study evaluating whether combinations of an OX40 agonist (ABBV-368), a TLR-9 agonist (tilsotolimod), chemotherapy (nab-paclitaxel) and/or an anti-programmed cell death 1 (PD-1) antagonist (ABBV-181) stimulate the immune system resulting in anti-tumor responses.
This Phase 1b, multi-center, open-label study is designed to determine the safety, tolerability, pharmacokinetics and preliminary efficacy of combinations of ABBV-368 plus tilsotolimod in subjects with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The study will test three separate treatment arms:- ABBV-368 plus tilsotolimod;
- ABBV-368 plus tilsotolimod and nab-paclitaxel; and
- ABBV-368 plus tilsotolimod, nab-paclitaxel and ABBV-181.